Baricitinib Provides Significant Improvements in Quality of Life and Functioning in Adults with Moderate-to-Severe Atopic Dermatitis with Baseline Body Surface Area ≤ 40% and Severe Itch
Despite having high QoL impairment at baseline, patients with itch-dominant AD treated with BARI 4 mg showed marked benefits in QoL, daily life activity, and work function compared to placebo after 16 weeks of treatment. Limitations include the small sample size analyzed.
Authors
- Z. Reguiaï (ORCID: https://orcid.org/0000-0002-9177-8525)
- Toshifumi Nomura (ORCID: https://orcid.org/0000-0002-9954-6446)
- C. Elise Kleyn
- Maddalena Napolitano (ORCID: https://orcid.org/0000-0003-3309-8190)
- Matthias Augustin (ORCID: https://orcid.org/0000-0002-4026-8728)
- Rosa Izu-Belloso
- Silvia Sabatino
- Susanne Grond (ORCID: https://orcid.org/0000-0002-7121-9013)
- Chunyuan Liu
- Joaquin R. Otero-Asman
Institutions
- University of Tsukuba (JP)
- Universität Hamburg (DE)
- Eli Lilly (United States) (US)
- Salford Royal NHS Foundation Trust (GB)
- National Institute for Health and Care Research (GB)
- Hospital de Basurto (ES)
- University Medical Center Hamburg-Eppendorf (DE)
- Polyclinique de Franche Comté (FR)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-01-29
- DOI
- https://doi.org/10.1007/s13555-024-01330-w
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company